Recursion Pharmaceuticals, an emerging biotechnology company today announced it has hired Dr. Chand Sishta as the senior director of regulatory affairs. Chand joins the company after 25 years in regulatory sciences, most recently at Bristol-Myers Squibb as the Director of Global Regulatory Sciences for Mature Products, where he led regulatory activities in many countries and where he was the FDA liaison in multiple therapeutic areas.
Recursion Pharmaceuticals is preparing to take their first discoveries through Investigational New Drug (IND) approval and the start of clinical trials. Further, as Recursion advances towards its ultimate goal of 100 new treatments by 2025, new modes of thinking about all phases of discovery and development are needed. Sishta’s drug development experience across the domains of quality assurance (QA); chemistry, manufacturing and controls (CMC); and regulatory affairs will be integral to the company in navigating this process.
“I’m really excited to join this fast-growing company focused on new treatments for rare diseases, and beyond,” said Sishta. “And to provide inventive regulatory affairs solutions in a fast-paced start-up environment.”
Recursion Pharmaceutical’s discovery platform harnesses the power of technology to repurpose drugs and shelved assets, as well as discover new chemical entities, mapping them to rare conditions, diseases of inflammation and immuno-oncology, among others. The potential of the platform to bring new treatments to conditions much faster than previous methods has positioned the company to the high-growth stage it is in today.
“Chand’s experience in regulatory affairs, QA and CMC is critical at this juncture of Recursion’s growth,” said Chris Gibson, CEO and co-founder of Recursion. “The addition of Chand to our leadership team will help us achieve our goal to deliver treatments to patients faster, and to rethink efficiency as we leverage technologies like artificial intelligence across the pipeline of discovery through development.”
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, and in vivo validation capabilities with a highly cross-functional team to discover novel medicines and expand our collective understanding of biology. Recursion’s rich, relatable database of 4 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at www.recursionpharma.com or connect on www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.